Abstract
This article provides an insightful overview of recent advancements and significant events in organoid research and technology. It covers the transition of HUB Organoids to a private company, the inaugural meeting of the International Society of Organoid Research in Singapore, and developments in organoid group standards at Tsinghua Changgeng Hospital. Additionally, it highlights breakthroughs in automated culture technology, major acquisitions such as Roche's purchase of Herophilus, and substantial funding rounds like Seraxis's $50 million for diabetes organoid therapy, demonstrating the dynamic growth and potential of this field.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
